💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Gadobutrol

CHEMBL2218860 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
604.7 g/mol
LogP
—
Phase
4

This gadolinium-based MRI contrast agent has a high concentration formulation that enhances the visibility of tumors and other abnormalities in the brain, spine, and blood vessels. Its high relaxivity and stability make it suitable for a wide range of diagnostic imaging applications.

分子量

604.7000 g/mol

TPSA

194.00 Ų

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Lymphoma Hypertension Breast Cancer Hepatitis C Heart Failure Prostate Cancer Colorectal Cancer

作用机制

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])[C@H](CO)[C@@H](CO)O)CC(=O)[O-].[Gd+3]

                

                

                
                

                    
InChI

                    
InChI=1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H31GdN4O9

                    

                    
                    

                        
HBD / HBA

                        
3 / 13

                    

                    
                    

                        
可旋转键数

                        
7

                    

                    
                    
                    

                        
重原子数

                        
32

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
This gadolinium-based MRI contrast agent has a high concentration formulation that enhances the visibility of tumors and other abnormalities in the brain, spine, and blood vessels. Its high relaxivity and stability make it suitable for a wide range of diagnostic imaging applications.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Gadobutrol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2218860.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6102852.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.